Navigation Links
AVANT Immunotherapeutics Announces Oral Presentation of CDX-110 at ASCO Annual Meeting
Date:5/22/2008

PHILLIPSBURG, N.J., May 22 /PRNewswire-FirstCall/ -- Celldex Therapeutics (a wholly-owned subsidiary of AVANT Immunotherapeutics)(Nasdaq: AVAN) announced today that its lead product candidate, CDX-110, being developed for the treatment of Glioblastoma Multiforme (GBM), will be the subject of an oral presentation at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO). The ASCO meeting will be held at McCormick Place in Chicago from May 30 through June 3, 2008.

The oral presentation, scheduled for Monday, June 2 from 10:00 - 10:15 a.m. CDT in room S406 (Vista Room), will include median survival data from ACTIVATE, a phase IIa clinical trial, and data from ACT II, the extension arm of the study. The presentation will be given by John H. Sampson, MD, PhD, Associate Professor of Neurosurgery at Duke University Medical Center.

On April 16, 2008, Pfizer, Inc. and Celldex entered into an agreement that granted Pfizer an exclusive worldwide license to CDX-110, an investigational vaccine currently in development for the treatment of GBM.

About CDX-110

CDX-110 is designed to induce or enhance the body's immune responses against epidermal growth factor variant III (EGFRvIII) and may lead to destruction of tumor cells that express this variant receptor. A randomized Phase 2 trial is currently enrolling at 24 sites across the United States.

About Glioblastoma Multiforme

GBM is the most common form of primary brain tumor. It is an aggressive tumor with very poor prognosis.(1) There are an estimated 10,000 new cases of GBM annually in the United States, which predominantly affects adults aged 45 to 70. Current GBM treatment options include surgical resection, radiotherapy and chemotherapy.

(1) Uddin S, Jarmi T. Glioblastoma Multiforme. Available at

http://www.emedicine.com/NEURO/topic147.htm. Accessed May 6, 2008.

About AVANT Immunotherapeutics, Inc.

AVANT Immunotherapeutics and Celldex Therapeutics combined during the first quarter of 2008. AVANT is a NASDAQ-listed company discovering and developing innovative vaccines and targeted immunotherapeutics for the treatment of cancer, infectious and inflammatory diseases. AVANT focuses on the use of tumor-specific targets and human monoclonal antibodies (mAbs) to precisely deliver therapeutic agents through its novel "targeted immunization" approach. In addition, AVANT is exploiting its access to proprietary human antibody technology for development of therapeutic monoclonal antibodies (mAbs). AVANT's deep product pipeline consists of products in varying stages of development. Identification of the potential of EGFRvIII in cancer diagnosis, prevention and therapy was based on the collaborative efforts of Dr. Bert Vogelstein and Dr. Albert Wong at Johns Hopkins University and Dr. Darell Bigner at Duke University. Application of this discovery toward the development of the CDX-110 vaccine was further advanced by Dr. John Sampson and his colleagues at the Duke University Brain Tumor Center in collaboration with Dr. Amy Heimberger at the MD Anderson Cancer Center. AVANT also has several product candidates in its development pipeline including:

-- CDX-1307, a product based on its proprietary APC Targeting

Technology(TM), which is in two Phase 1 clinical trials for patients

with advanced pancreatic, bladder, breast and colon cancer;

-- TP10, a complement inhibitor, in development for transplantation and

other indications; and

-- Three candidates based on oral, rapidly-protecting, single-dose and

temperature-stable vaccine technology, including combination vaccines

for travellers, the military and global health needs.

AVANT has three commercialized products, including Rotarix(R) (partnered with GSK) for the prevention of rotavirus infection and two human food safety vaccines for reducing salmonella infection in chickens and eggs. Additional information on AVANT Immunotherapeutics, Inc. can be obtained through its web site http://www.avantimmune.com.

Contact: Marissa Nelson

BMC Communications

+1-212-477-9007 x21


'/>"/>
SOURCE AVANT Immunotherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Exelixis Announces June 2 Webcast of Its ASCO Investor and Analyst Briefing
2. Biopure Announces 2008 Second Quarter Financial Results
3. NeoStem Announces Private Placement Financing to Advance Marketing Campaign; Financing Includes Investment from New England Cryogenic Center
4. Rentschler Biotechnologie Announces Cooperation with Boehringer Ingelheim
5. Still River Systems Announces Operation of the Worlds Highest Magnetic Field Cyclotron
6. Aton Pharma Announces Distribution Partnership in the Asia Pacific Region
7. Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG
8. eResearchTechnology Announces Resignation of its CFO
9. Biodel Inc. Announces Appointment of Alan Krasner, M.D. as Chief Medical Officer
10. Oncolytics Biotech Inc. Announces Issuance of 27th U.S. Patent
11. Amarin Announces Financial Results for Fourth Quarter and Full Year 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed for ... complexity. Named in honor of pioneering researcher Rosalind Franklin, who made a ...
(Date:10/11/2017)... Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... set to take place on 7th and 8th June 2018 in San Francisco, CA. ... policy influencers as well as several distinguished CEOs, board directors and government officials from ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the main ... people each year. Especially those living in larger cities are affected by air pollution ... of the most pollution-affected countries globally - decided to take action. , “I knew ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
Breaking Biology Technology:
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
(Date:4/13/2017)... SANTA MONICA, Calif. , April 13, 2017 /PRNewswire/ ... New York will feature emerging and ... Innovation Summits. Both Innovation Summits will run alongside the ... variety of speaker sessions, panels and demonstrations focused on ... east coast,s largest advanced design and manufacturing event will ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and ... Market 2017-2021" report to their offering. ... The global eye tracking market to grow at a ... report, Global Eye Tracking Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
Breaking Biology News(10 mins):